Literature DB >> 18053707

A Greenwood formula for standard error of the age-standardised relative survival ratio.

Arun Pokhrel1, Tadeusz Dyba, Timo Hakulinen.   

Abstract

The age-standardised relative survival ratio is used to compare population-based cancer survival patterns when the population age structures differ. Traditionally, the direct standardisation method based on age-specific relative survival ratios has been used. In a new method [Brenner H, Arndt V, Gefeller O, Hakulinen T. An alternative approach to age adjustment of cancer survival rates. Eur J Cancer 2004;40:2317-22], weighted observations depending on the age structures of the study and standard populations are used to substitute the patients leading to a use of weighted counts. The relative survival ratio is then calculated in the conventional way. However, no standard error of the age-standardised relative survival estimate has been reported. In this paper, we introduce a generalisation of the well-known Greenwood formula for that purpose. This method is also applicable for the observed survival and particularly when the observed survival probabilities of the patient population differ by age stratum. The traditional Greenwood formula is a special case of the method when no specific weights are used and the observed survival probability is the same in each stratum. Data from the Finnish Cancer Registry are used for illustration.

Entities:  

Mesh:

Year:  2007        PMID: 18053707     DOI: 10.1016/j.ejca.2007.10.026

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  5 in total

1.  Linear accelerator-based stereotactic body radiation therapy in the treatment of oligometastatic disease.

Authors:  Hideomi Yamashita; Mami Ogita; Shuri Aoki; Osamu Abe; Keiichi Nakagawa
Journal:  Mol Clin Oncol       Date:  2020-06-09

2.  African-American and Caucasian mortalities are the same after traumatic injury: pair matched analysis from a national data.

Authors:  Nasim Ahmed; David Kountz; Yenhong Kuo
Journal:  Trauma Surg Acute Care Open       Date:  2020-03-31

3.  A phase 2 multicenter trial of ofatumumab and prednisone as initial therapy for chronic graft-versus-host disease.

Authors:  Aleksandr Lazaryan; Stephanie Lee; Mukta Arora; Jongphil Kim; Brian Christopher Betts; Farhad Khimani; Taiga Nishihori; Nelli Bejanyan; Hien Liu; Mohamed A Kharfan-Dabaja; Frederick L Locke; Rebecca Gonzalez; Michael D Jain; Marco L Davila; Lia Elena Perez; Asmita Mishra; Ariel Perez Perez; Karlie Balke; Ernesto Ayala; Leonel Ochoa; Omar Castaneda Puglianini; Rawan Faramand; Melissa Alsina; Hany Elmariah; Michael L Nieder; Hugo Fernandez; Claudio Anasetti; Joseph A Pidala
Journal:  Blood Adv       Date:  2022-01-11

4.  Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study.

Authors:  Zhi Peng; Tianshu Liu; Jia Wei; Airong Wang; Yifu He; Liuzhong Yang; Xizhi Zhang; Nanfeng Fan; Suxia Luo; Zhen Li; Kangsheng Gu; Jianwei Lu; Jianming Xu; Qingxia Fan; Ruihua Xu; Liangming Zhang; Enxiao Li; Yuping Sun; Guohua Yu; Chunmei Bai; Yong Liu; Jiangzheng Zeng; Jieer Ying; Xinjun Liang; Nong Xu; Chao Gao; Yongqian Shu; Dong Ma; Guanghai Dai; Shengmian Li; Ting Deng; Yuehong Cui; Jianmin Fang; Yi Ba; Lin Shen
Journal:  Cancer Commun (Lond)       Date:  2021-10-19

5.  DetecDiv, a generalist deep-learning platform for automated cell division tracking and survival analysis.

Authors:  Théo Aspert; Didier Hentsch; Gilles Charvin
Journal:  Elife       Date:  2022-08-17       Impact factor: 8.713

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.